Shazia Bukhari – författare

This volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis. It incudes conventional and advanced cancer therapies ranging from oral and parenteral preparations to advanced fabricated systems such as nanoparticles, liposomes, antibodies, aptamers, poly(amidoamine) and photodynamic therapies. The preparation and mechanisms of molecular targeting of cancer are presented and the authors focus on a diverse audience including undergraduates and research students.

Features

Timely coverage of changes in process control technology for the phamaceutical industry, a dynamic area in terms of products and manufacturing processes Provides an update on the unique requirements of these industries and how they differ from others, for example the microelectronics or specialized chemicals industries Draws on the author''s vast experience in the field of industrial hygiene and hazardous materials Presents a collection of unique situations in which industrial hygiene was implemented to resolve a variety of scenarios and did not interfere with quality issues Addresses current topics relating to industry evolution such as migration of therapies to higher potency, RiskMAP, new modalities in medicines and treatments, large molecule therapeutics and conjugates

This volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis. It incudes conventional and advanced cancer therapies ranging from oral and parenteral preparations to advanced fabricated systems such as nanoparticles, liposomes, antibodies, aptamers, poly(amidoamine) and photodynamic therapies. The preparation and mechanisms of molecular targeting of cancer are presented and the authors focus on a diverse audience including undergraduates and research students.

Features

Timely coverage of changes in process control technology for the phamaceutical industry, a dynamic area in terms of products and manufacturing processes Provides an update on the unique requirements of these industries and how they differ from others, for example the microelectronics or specialized chemicals industries Draws on the author''s vast experience in the field of industrial hygiene and hazardous materials Presents a collection of unique situations in which industrial hygiene was implemented to resolve a variety of scenarios and did not interfere with quality issues Addresses current topics relating to industry evolution such as migration of therapies to higher potency, RiskMAP, new modalities in medicines and treatments, large molecule therapeutics and conjugates

This volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis. It incudes conventional and advanced cancer therapies ranging from oral and parenteral preparations to advanced fabricated systems such as nanoparticles, liposomes, antibodies, aptamers, poly(amidoamine) and photodynamic therapies. The preparation and mechanisms of molecular targeting of cancer are presented and the authors focus on a diverse audience including undergraduates and research students.FeaturesTimely coverage of changes in process control technology for the phamaceutical industry, a dynamic area in terms of products and manufacturing processesProvides an update on the unique requirements of these industries and how they differ from others, for example the microelectronics or specialized chemicals industriesDraws on the author's vast experience in the field of industrial hygiene and hazardous materialsPresents a collection of unique situations in which industrial hygiene was implemented to resolve a variety of scenarios and did not interfere with quality issuesAddresses current topics relating to industry evolution such as migration of therapies to higher potency, RiskMAP, new modalities in medicines and treatments, large molecule therapeutics and conjugates